Skip to main content

Advertisement

SpringerLink
Log in

Pulmonary Hypertension, Antiphospholipid Antibodies, and Syndromes

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Antiphospholipid antibodies have been associated with two types of pulmonary hypertension (PHT), the thromboembolic type, after deep venous thromboses in the lower limbs complicated by pulmonary embolism and the “primary” plexogenic type. The PHT may occur in the absence of any other manifestations of the antiphospholipid syndrome (APS), and cases have been recorded with very high levels of antiphospholipid antibodies. It may also accompany systemic lupus erythematosus (SLE) and may manifest with or without other features of the APS. It may also form part of the clinical presentation of a “primary” APS. Its prevalence is of the order of 1.8–3.5% of the manifestations of the APS depending on the series. Primary “idiopathic” PHT has long been regarded as an “immunological” disorder. Its manifestations are essentially to the primary type seen with the connective tissue disorders such as SLE, APS, mixed connective tissue disease, calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia variety of systemic sclerosis and Sjögren’s syndrome. The high prevalence of PHT in patients with human immunodeficiency virus infection who demonstrate low CD4 counts points to a close relationship between the T regulatory cells (Treg) and the development of PHT, and this hypothesis is discussed in this review. Genetic and chromosomal aspects of PHT are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Humbert M (2007) Post-marketing surveillance survey of use of bosetan in pulmonary arterial hypertension. Oral presentation ATS annual meeting. TRAX data on file. Actelion

  2. Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicentre study of 114 patients. Am J Med 9:3–9

    Article  Google Scholar 

  3. McCarty GA (2000) Vascular pathology of the antiphospholipid syndrome. In: Khamashta MA (ed) Hughes syndrome: the antiphospholipid syndrome. Springer, London, pp 263–280

    Google Scholar 

  4. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT (2002) The antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46:1019–1027

    Article  PubMed  Google Scholar 

  5. Simonneau G, Galie N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S–12S

    Article  PubMed  Google Scholar 

  6. Moser KM, Auger WR, Fedullo PF (1990) Chronic major vessel thromboembolic pulmonary hypertension. Circulation 81:1735–1743

    PubMed  CAS  Google Scholar 

  7. Jamieson SW, Auger WR, Fedullo PF et al (1993) Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 106:116–127

    PubMed  CAS  Google Scholar 

  8. Sandoval J, Amigo MC, Barragan R et al (1996) Primary antiphospholipid syndrome presenting as chronic thromboembolic hypertension. Treatment with thromboendarterectomy. J Rheumatol 23:772–775

    PubMed  CAS  Google Scholar 

  9. Bendayan D, Shitrit D, Kramer MR (2006) Pulmonary arterial hypertension associated with autoimmune disease: a single medical center experience. Isr Med Assoc J 8(4):252–254

    PubMed  Google Scholar 

  10. Cervera R, Asherson RA (2006) Primary pulmonary arterial hypertension and the systemic autoimmune diseases. Isr Med Assoc J 8(4):277–279 (editorial)

    PubMed  Google Scholar 

  11. Holt PJ, Clague RB, Hay FC, Nineham IJ, Wade EG (1980) Is idiopathic pulmonary hypertension a connective tissue disease? Arthritis Rheum 23:690 (abstract)

    Google Scholar 

  12. Rich S, Kieras K, Hait K, Groves BM, Stobo JD, Brundage BH (1986) Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 8:1307–1311

    Article  PubMed  CAS  Google Scholar 

  13. Isern RA, Yaneva M, Weiner E et al (1992) Autoantibodies in patients with primary pulmonary hypertension; association with anti-Ku. Am J Med 93:307–312

    Article  PubMed  CAS  Google Scholar 

  14. Yanai-Landau H, Amital H, Bar-Dayan Y et al (1995) Autoimmune aspects of primary pulmonary hypertension. Pathobiology 63:71–75

    Article  PubMed  CAS  Google Scholar 

  15. Karmochkine M, Cacoub P, Dorent R et al (1996) High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 23:286–290

    PubMed  CAS  Google Scholar 

  16. Nicolls MR, Tarasevicience-Stewart L, Rai PR, Badesch DB, Voelkel NF (2005) Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 26:1110–1118

    Article  PubMed  CAS  Google Scholar 

  17. Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev 1:329–337

    Article  PubMed  CAS  Google Scholar 

  18. Hoeper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H (1999) Pulmonary hypertension after splenectomy? Ann Intern Med 130:506–509

    PubMed  CAS  Google Scholar 

  19. Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R (2003) Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J 22:709–711

    PubMed  CAS  Google Scholar 

  20. Lloyd J, Newman J (1997) Familial primary pulmonary hypertension. Marcel Dekker, New York

    Google Scholar 

  21. Loscalzo J (2001) Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 345:367–371

    Article  PubMed  CAS  Google Scholar 

  22. Nichols WC, Koller DL, Slovis B et al (1997) Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat Genet 15:277–280

    Article  PubMed  CAS  Google Scholar 

  23. Sakaguchi S (2004) Naturally arising CD4 regulatory CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2002:531–562

    Article  CAS  Google Scholar 

  24. Deng Z, Morse JH, Slager S et al (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-11 gene. Am J Hum Genet 67:737–744

    Article  PubMed  CAS  Google Scholar 

  25. Negi VS, Tripathy NK, Misra R, Nityanand S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462–466

    PubMed  CAS  Google Scholar 

  26. Renaudineau Y, Dugue C, Dueymes M, Youinou P (2002) Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 1:427–438

    Google Scholar 

  27. Sasaki N, Kurose AQ, Inoue H, Sawai TA (2002) Possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension. Ryumachi 42:885–894

    PubMed  Google Scholar 

  28. Longo F, Saletta S, Lepore L, Pennnesi M (1993) Localized scleroderma after infection with Epstein–Barr virus. Clin Exp Rheumatol 11:681–683

    PubMed  CAS  Google Scholar 

  29. Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M (2004) Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol 31:43–50

    Article  PubMed  Google Scholar 

  30. Ferri C, Longombardo G, Mugnaini P (1998) Hepatitis E virus and systemic sclerosis. QJM 91:375

    Article  PubMed  CAS  Google Scholar 

  31. Ferri C, Zakrewska K, Longombardo G et al (1999) Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 17:718–720

    PubMed  CAS  Google Scholar 

  32. Harel L, Strausberg R, Rudich H, Cohen AH, Amir J (2000) Raynaud’s phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitis syndrome. Clin Infect Dis 30:500–503

    Article  PubMed  CAS  Google Scholar 

  33. Abu-Shakra M, Sukenik S, Buskila D (2000) Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. Clin Rheumatol 19:378–380

    Article  PubMed  CAS  Google Scholar 

  34. Neidhart M, Kuchen S, Distler O et al (1999) Increased serum levels of antibodies against cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 42:389–392

    Article  PubMed  CAS  Google Scholar 

  35. Miyata M, Suzuki K, Sakuma F et al (1993) Anticardiolipin antibodies are associated with pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus. Int Arch Allergy Immunol 100(4):351–354

    Article  PubMed  CAS  Google Scholar 

  36. Hainaut P, Lauvenne E, Magy JM, Lebacq EG (1986) Circulating lupus anticoagulant and pulmonary hypertension associated with mixed connective tissue disease. Clin Rheumatol 5:96–101

    Article  PubMed  CAS  Google Scholar 

  37. Asherson RA, Mackworth-Young CG, Boey CG et al (1983) Pulmonary Hypertension in systemic lupus erythematosus. Br Med J 287:1024–1025

    CAS  Google Scholar 

  38. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GRV (1986) Pulmonary hypertension in systemic lupus erythematosus. A report of three cases. Rheumatol 12:416–420

    Google Scholar 

  39. Alarcon Segovia D, Deleze M, Oria CV et al (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68:353–365

    CAS  Google Scholar 

  40. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GRV (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292–1298

    PubMed  CAS  Google Scholar 

  41. Sato M, Okazaki H, Okamoto H et al (1994) Pulmonary hypertension in systemic lupus eythematosus; report of an autopsied case. Intern Med 33:540–542

    PubMed  CAS  Google Scholar 

  42. Nagai H, Yasuma K, Katsuki T et al (1997) Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival. A case report. Angiology 48:183–187

    Article  PubMed  CAS  Google Scholar 

  43. Luchi ME, Asherson RA, Lahita RG (1992) Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis. Asssociation with antiphospholipid antibodies. Arthritis Rheum 35:700–705

    Article  PubMed  CAS  Google Scholar 

  44. De la Mata J, Gomez-Sanchez MA, Aranaza M, Gomez-Reino JJ (1994) Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 37:1528–1533

    Article  PubMed  Google Scholar 

  45. Rana M, Endo H, Watabe H, Tanaka S, Kondo H (2001) A case of primary antiphospholipid syndrome complicated with pulmonary hypertension. Ryumachi 41:869–874

    PubMed  CAS  Google Scholar 

  46. Assous N, Allanore Y, Batteux F et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23:199–204

    PubMed  CAS  Google Scholar 

  47. Asherson RA, Shepselovich, D, Cervera R, Shoenfeld Y (2006) Non thrombotic manifestations of the antiphospholipid syndrome: away from thrombosis? Editorial J Rheumatol (in press)

Download references

Author information

Authors and Affiliations

  1. Division of Immunology, School of Pathology, University of the Witwatersrand and the Rosebank Clinic, Johannesburg, 2000, South Africa

    Ronald A. Asherson

  2. Systemic Autoimmune Diseases Unit, Hospital Clinic, Barcelona, Catalonia, Spain

    Ricard Cervera

Authors
  1. Ronald A. Asherson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricard Cervera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald A. Asherson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Asherson, R.A., Cervera, R. Pulmonary Hypertension, Antiphospholipid Antibodies, and Syndromes. Clinic Rev Allerg Immunol 32, 153–158 (2007). https://doi.org/10.1007/s12016-007-0012-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-0012-0

Keywords

Search

Navigation